吉林长龙药业(08049)发布中期业绩，股东应占溢利1.03亿元，同比下降1.2%

Core Insights - Jilin Changlong Pharmaceutical (08049) reported a revenue of 439 million RMB for the six months ending June 30, 2025, representing a year-on-year growth of 11.6% [1] - The profit attributable to shareholders was 103 million RMB, showing a slight decline of 1.2% compared to the previous year [1] - The basic earnings per share stood at 18.38 cents [1] Financial Performance - The gross margin for the period was approximately 82.4%, which is an increase compared to the period ending June 30, 2024 [1] - The board attributes the improved gross margin to a reduction in production and material costs [1]